HONZ PHARMACEUTICAHH

HONZ PHARMACEUTICA

7.88CNYD
+0.27+3.55%
As of today at 03:02 GMT
CNY
No trades
See on Supercharts

300086 fundamentals

Key facts

Market capitalization‪3.46 B‬CNY
Basic EPS (TTM)−0.40CNY
Founded1994
CEOJiang Tao Hong
About

Honz Pharmaceutical Co., Ltd. engages in the manufacture and distribution of drugs for children. It offers western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant, and arresting convulsion drugs. Its products include nimesulide granules, cefminox sodium for injection, zhike juhong granules, ganmao qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, jianerle granules, pediatric vitamins, calcium gluconate granules, ribavirin pellets, and Norfloxacin capsules for adults. The company was founded on January 20, 1994 and is headquartered in Guangzhou, China.

Ownership
‪‪455.12 M‬‬
Free Float shares
‪‪266.67 M‬‬ (58.59%)
Closely held shares
‪‪188.46 M‬‬ (41.41%)
Free Float shares
‪‪266.67 M‬‬ (58.59%)
Closely held shares
‪‪188.46 M‬‬ (41.41%)
Capital structure
Market cap
‪‪3.46 B‬‬
Debt
‪‪528.09 M‬‬
Minority interest
‪‪24.83 M‬‬
Cash & equivalents
‪‪92.97 M‬‬
Enterprise value
‪‪3.92 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪3.46 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.36x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.36x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪1.30‬
‪2.60‬
‪3.90‬
‪5.20‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−92.5%‬
‪−71.5%‬
‪−50.5%‬
‪−29.5%‬
‪−8.5%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−160.00 M‬‬
‪‪−80.00 M‬‬
‪0.00‬
‪‪80.00 M‬‬
‪‪160.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−40.00 M‬‬
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−40.00 M‬‬
‪0.00‬
‪‪40.00 M‬‬
‪‪80.00 M‬‬
‪‪120.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceutical Production and Sales
Daily Necessities Production and Sales
By country
Period: 2024
China
Overseas

Dividends

Dividend yield, history and sustainability

Dividend summary
0.00%
Payout ratio (TTM)
Dividend yield TTM
0.00%
Last payment
Last ex-date
Last pay date
Dividend history
‪0.0%‬
‪0.1%‬
‪0.2%‬
‪0.3%‬
‪0.4%‬
2020
2021
2022
2023
2024
‪0.00‬
‪0.01‬
‪0.01‬
‪0.01‬
‪0.02‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−200.00 M‬‬
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬
Assets
Liabilities